PT812588E - Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria - Google Patents

Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria

Info

Publication number
PT812588E
PT812588E PT96942623T PT96942623T PT812588E PT 812588 E PT812588 E PT 812588E PT 96942623 T PT96942623 T PT 96942623T PT 96942623 T PT96942623 T PT 96942623T PT 812588 E PT812588 E PT 812588E
Authority
PT
Portugal
Prior art keywords
diol
amino
topical administration
opopane
ocylphenyl
Prior art date
Application number
PT96942623T
Other languages
English (en)
Inventor
Koji Teshima
Tadashi Mishina
Tsuneo Fujii
Tomonori Imayoshi
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of PT812588E publication Critical patent/PT812588E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PT96942623T 1995-12-28 1996-12-24 Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria PT812588E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP34250395 1995-12-28

Publications (1)

Publication Number Publication Date
PT812588E true PT812588E (pt) 2005-01-31

Family

ID=18354257

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96942623T PT812588E (pt) 1995-12-28 1996-12-24 Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria

Country Status (16)

Country Link
US (2) US6121329A (pt)
EP (1) EP0812588B1 (pt)
AT (1) ATE279185T1 (pt)
AU (1) AU705320B2 (pt)
CA (1) CA2213989C (pt)
CZ (1) CZ285953B6 (pt)
DE (1) DE69633613T2 (pt)
ES (1) ES2230571T3 (pt)
HU (1) HU224814B1 (pt)
IL (1) IL121625A (pt)
NZ (1) NZ324453A (pt)
PT (1) PT812588E (pt)
RU (1) RU2156127C2 (pt)
SI (1) SI0812588T1 (pt)
SK (1) SK282225B6 (pt)
WO (1) WO1997024112A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
AU735406B2 (en) * 1997-02-27 2001-07-05 Novartis Ag Pharmaceutical composition
ATE363275T1 (de) * 1998-04-27 2007-06-15 Astellas Pharma Inc Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US7683044B2 (en) * 1999-03-25 2010-03-23 Center For Molecular Medicine And Immunology Sphingomyelin therapy of autoimmune disease
CA2368676C (en) * 1999-03-25 2010-09-07 Center For Molecular Medicine And Immunology Sphingomyelin containing preparation
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
WO2002067915A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
CA2473461C (en) * 2002-01-11 2011-11-01 Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
US20040014662A1 (en) 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
CN1738610A (zh) * 2003-01-22 2006-02-22 日绊株式会社 眼疾治疗用经皮吸收型制剂、其使用及眼疾治疗药向眼局部组织的转移方法
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
RU2358716C2 (ru) 2003-04-08 2009-06-20 Новартис Аг Органические соединения
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
JP2007505125A (ja) * 2003-09-09 2007-03-08 スリーエム イノベイティブ プロパティズ カンパニー 抗菌性組成物および方法
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
KR101182619B1 (ko) 2004-02-24 2012-09-18 상꾜 가부시키가이샤 아미노 알코올 화합물
US20050232894A1 (en) * 2004-04-20 2005-10-20 Weiner Gregory M Antimicrobial skin treatment composition and methods for producing and using an antimicrobial skin treatment composition
KR101174930B1 (ko) * 2004-07-30 2012-08-17 노파르티스 아게 ２-아미노-１,３-프로판디올 화합물의 화합물 제제
KR20070083941A (ko) * 2004-10-04 2007-08-24 큐엘티 유에스에이, 인코포레이티드 중합체 전달 조성을 갖는 눈 전달
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
BRPI0518674A2 (pt) * 2004-11-29 2008-12-02 Novartis Ag regime de dosagem de um agonista de receptor s1p
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
US8476319B2 (en) 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
CN101175474B (zh) 2005-03-10 2011-09-07 3M创新有限公司 降低微生物污染的方法
US9826770B2 (en) 2005-03-10 2017-11-28 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
WO2006102611A2 (en) * 2005-03-24 2006-09-28 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
US20080009545A1 (en) * 2006-02-21 2008-01-10 The Ohio State University Research Foundation Anticancer agents
ES2414205T3 (es) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
AU2008310846C1 (en) 2007-10-12 2022-10-06 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
BRPI0909625B1 (pt) 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
AU2010236655A1 (en) * 2009-04-13 2011-11-17 The Ohio State University Research Foundation Protein phosphatase 2A-activating agents
AU2010236323A1 (en) * 2009-04-17 2011-11-24 The Ohio State University Research Foundation Antiadhesion agents
EP2456752A2 (en) 2009-07-24 2012-05-30 ratiopharm GmbH Process for producing fingolimod salts
CN101966145A (zh) * 2010-09-21 2011-02-09 浙江大学 2-氨基-2-(2-[4-辛基苯基]乙基)-1,3-丙二醇盐酸盐制剂及其制备方法
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
CN105611917A (zh) 2013-10-11 2016-05-25 帝国制药美国公司 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
US10798783B2 (en) * 2017-02-15 2020-10-06 Continuous Composites Inc. Additively manufactured composite heater
MX2020000029A (es) * 2017-07-05 2020-08-06 Jiangyin Mucocare Pharmaceutical Co Ltd Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
EP0501579A1 (en) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalene lactones as inhibitors of leukotriene biosynthesis
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
IT1252866B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica
ES2126658T3 (es) * 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
JPH06256182A (ja) * 1993-03-05 1994-09-13 L T T Kenkyusho:Kk 外用製剤
JPH07188046A (ja) * 1993-12-27 1995-07-25 L T T Kenkyusho:Kk シクロスポリン含有外用治療薬及びその製造方法
EP0694308A4 (en) * 1994-02-17 1997-09-10 Shiseido Co Ltd CYCLOSPORIN EMULSION COMPOSITION
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法

Also Published As

Publication number Publication date
ES2230571T3 (es) 2005-05-01
DE69633613D1 (de) 2004-11-18
CZ270497A3 (cs) 1998-01-14
CZ285953B6 (cs) 1999-12-15
HU224814B1 (en) 2006-02-28
ATE279185T1 (de) 2004-10-15
IL121625A0 (en) 1998-02-08
AU705320B2 (en) 1999-05-20
EP0812588A4 (en) 2002-11-06
CA2213989A1 (en) 1997-07-10
AU1172997A (en) 1997-07-28
IL121625A (en) 2001-09-13
HUP9800034A3 (en) 1999-12-28
CA2213989C (en) 2007-05-29
WO1997024112A1 (fr) 1997-07-10
US6121329A (en) 2000-09-19
HUP9800034A2 (hu) 1999-05-28
EP0812588B1 (en) 2004-10-13
RU2156127C2 (ru) 2000-09-20
DE69633613T2 (de) 2006-02-09
SK115797A3 (en) 1998-02-04
NZ324453A (en) 2000-03-27
EP0812588A1 (en) 1997-12-17
SK282225B6 (sk) 2001-12-03
SI0812588T1 (en) 2005-02-28
US6197829B1 (en) 2001-03-06

Similar Documents

Publication Publication Date Title
PT812588E (pt) Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria
RU2221790C2 (ru) Новые производные пиридазина и лекарственные средства, содержащие их в качестве эффективных ингредиентов
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
BR0211742A (pt) Derivados de aminoisoxazole ativos como inibidores de cinase
DE69840169D1 (de) Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
PT1050301E (pt) Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
EP1201236A4 (en) MEDICAL COMPOSITIONS FOR PREVENTING THE TREATMENT OF VIRAL MYOCASCHITIS
YU25001A (sh) Optički aktivan derivat piridil-4h-1,2,4-oksadiazina i njegova upotreba u proizvodnji lekova za tretiranje vaskularnih bolesti
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
EA199901012A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
BR9712033A (pt) Composição farmacêutica para tratamento de doenças virais.
DE69314586T2 (de) Arzneimittelzusammensetzung enthaltend TCF-II
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase
BR0011845A (pt) Complexo farmacêutico
BR0308293A (pt) Terapia à base de estatina para aumentar a manutenção cognitiva
BR9915323A (pt) Derivados pirimidina e processos para sua preparação
BR9809127A (pt) Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
BR0114339A (pt) Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
ECSP972186A (es) Composicion terapeutica proveniente de la caña de azucar y sus usos terapeuticos
BR9809124A (pt) Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
BR112019005869A8 (pt) Derivados de cromano, isocromano e dihidroisobenzofurano como moduladores alostéricos negativos de mglur2, composições e seu uso
BR0106261A (pt) Composições medicamentosas contendo alcalóides indólicos para o tratamento da aids